Modern Chinese Medicine Group Co., Ltd. provided preliminary unaudited consolidated group earnings guidance for the six months 30 June 2023. For the period, the group expects to record a fall in profit attributable to the owners of the Company ranging from 40% to 50% as compared to that of the corresponding period in 2022 which amounted to approximately RMB 49.9 million. The expected fall in profit was primarily attributable to the rise in the costs of commonly used raw materials; and the substantial decrease in production of Vitality Supplement Pill, one of the top selling products of the Group, due to tight supply of the relevant raw materials, and therefore resulting in the overall decline in revenue.